Chronic Lymphocytic Leukemia CLL Mutations Detection Panel 2 Test
Comprehensive Genetic Analysis for CLL Management
The Chronic Lymphocytic Leukemia CLL Mutations Detection Panel 2 represents a cutting-edge molecular diagnostic approach specifically designed for patients with CLL. This comprehensive genetic panel utilizes advanced PCR-MLPA (Multiplex Ligation-dependent Probe Amplification) technology to detect critical mutations and chromosomal abnormalities that significantly influence disease prognosis and treatment response. By analyzing multiple genetic markers simultaneously, this test provides oncologists with essential information to develop personalized treatment strategies and predict disease outcomes.
What This Test Measures and Detects
Our CLL Mutations Detection Panel 2 comprehensively analyzes multiple genetic markers crucial for CLL management:
Key Gene Mutations
- SF3B1 K700E mutation – Associated with poor prognosis and treatment resistance
- MYD88 L265P mutation – Often indicates better prognosis and treatment response
- NOTCH1 p.2514 fs mutation – Linked to aggressive disease progression
- PTEN loss at 10q23.31 – Important for treatment selection and prognosis
Chromosomal Abnormalities
- 11q deletion – Associated with rapid disease progression
- Trisomy 12 – Intermediate prognostic indicator
- 13q14 deletion – Generally favorable prognosis marker
- 14q deletion – Important for disease monitoring
- 17p deletion – High-risk marker indicating poor prognosis
- Trisomy 19 – Additional chromosomal assessment
Who Should Consider This Test
This comprehensive genetic panel is recommended for individuals experiencing:
- Newly diagnosed Chronic Lymphocytic Leukemia
- Unexplained lymphocytosis or enlarged lymph nodes
- Fatigue, night sweats, or unexplained weight loss
- Recurrent infections or frequent illnesses
- Family history of CLL or hematologic malignancies
- Patients requiring treatment selection guidance
- Individuals with suspected Richter’s transformation
- Patients experiencing treatment resistance
Benefits of Taking the CLL Mutations Detection Panel 2
This advanced genetic testing offers numerous advantages for CLL patients:
- Personalized Treatment Planning – Enables targeted therapy selection based on specific genetic markers
- Prognostic Assessment – Provides valuable information about disease progression and outcomes
- Treatment Response Prediction – Helps anticipate how patients may respond to specific therapies
- Comprehensive Genetic Profile – Analyzes multiple mutations simultaneously for complete assessment
- Early Intervention Guidance – Supports timely treatment decisions for better outcomes
- Monitoring Disease Evolution – Tracks genetic changes over time for ongoing management
Understanding Your Test Results
Your CLL Mutations Detection Panel 2 results will provide detailed information about specific genetic markers:
Favorable Prognostic Markers
- Isolated 13q14 deletion typically indicates better prognosis
- MYD88 mutations often correlate with improved treatment response
- Normal karyotype may suggest standard disease course
High-Risk Genetic Markers
- 17p deletion requires specialized treatment approaches
- 11q deletion may indicate need for aggressive therapy
- TP53 mutations often necessitate targeted treatment strategies
- Complex karyotype suggests more challenging disease management
Your oncologist will interpret these results in the context of your overall health, symptoms, and treatment history to develop the most appropriate management plan.
Test Pricing and Information
| Test Name | Discount Price | Regular Price |
|---|---|---|
| Chronic Lymphocytic Leukemia CLL Mutations Detection Panel 2 Test | $126 USD | $188 USD |
Sample Requirements
- Sample Type: 4 mL (2 mL minimum) whole blood from 1 Lavender top (EDTA) tube
- Shipping: Ship refrigerated. DO NOT FREEZE
- Turnaround Time: Sample by Monday 11 AM; Report by Saturday
- Mandatory: Duly filled Genomics Clinical Information Requisition Form (Form 20)
Nationwide Availability
We have diagnostic centers across the United States, serving patients in all major metropolitan areas including New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, San Jose, Austin, Jacksonville, Fort Worth, Columbus, Charlotte, San Francisco, Indianapolis, Seattle, Denver, Washington DC, Boston, El Paso, Nashville, Detroit, Oklahoma City, Portland, Las Vegas, Memphis, Louisville, Baltimore, and Milwaukee.
Take Control of Your CLL Management Today
Don’t leave your treatment decisions to chance. Our comprehensive CLL Mutations Detection Panel 2 provides the genetic insights needed for informed medical decisions and personalized care. With advanced PCR-MLPA technology and expert analysis, you’ll receive accurate, reliable results that can significantly impact your treatment journey.
Ready to get started? Book your test now or call our genetic specialists at +1(267) 388-9828 to discuss your testing options and schedule your appointment.
Take the first step toward personalized CLL management and improved treatment outcomes with our comprehensive genetic analysis panel.
